Showing results (11-20 of 307) with videos related to
Sort By:
Pageof 31
The Journal of Clinical Endocrinology and Metabolism|February 14, 2025
Jansen's disease: bone abnormalities beyond chondrodysplasiaRenata C Pereira, Anne M Delany, Monica Reyes, et al.Pediatric Nephrology (Berlin, Germany)|February 4, 2005
Are new vitamin D analogues in renal bone disease superior to calcitriol?Isidro B SaluskyJournal of the American Society of Nephrology : JASN|June 10, 2005
Sevelamer controls parathyroid hormone-induced bone disease as efficiently as calcium carbonate without increasing serum calcium levels during therapy with active vitamin D sterolsIsidro B Salusky, William G Goodman, Shobha Sahney, et al.The Journal of Clinical Endocrinology and Metabolism|December 8, 2009
Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically activeTakashi Shimada, Itaru Urakawa, Tamara Isakova, et al.Kidney International|September 24, 2010
Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidismKatherine Wesseling-Perry, Renata C Pereira, Shobha Sahney, et al.The Journal of Clinical Endocrinology and Metabolism|December 4, 2008
Relationship between plasma fibroblast growth factor-23 concentration and bone mineralization in children with renal failure on peritoneal dialysisKatherine Wesseling-Perry, Renata C Pereira, Hejing Wang, et al.Pediatric Nephrology (Berlin, Germany)|March 21, 2009
Response of different PTH assays to therapy with sevelamer or CaCO3 and active vitamin D sterolsKatherine Wesseling-Perry, G Chris Harkins, He-Jing Wang, et al.Clinical Journal of the American Society of Nephrology : CJASN|August 27, 2016
Fibroblast Growth Factor 23 and Risk of CKD Progression in ChildrenAnthony A Portale, Myles S Wolf, Shari Messinger, et al.Proceedings of the National Academy of Sciences of the United States of America|April 18, 2025
Bidirectional disruption of GNAS transcripts causes broad methylation defects in pseudohypoparathyroidism type 1BYorihiro Iwasaki, Monica Reyes, Anna Ryabets-Lienhard, et al.American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|November 15, 2011
Evaluation of hypophosphatemia: lessons from patients with genetic disordersJustine Bacchetta, Isidro B SaluskyPageof 31